Implications of Withaferin-A for triple-negative breast cancer chemoprevention

Area of Science:

• Oncology
• Pharmacology
• Natural Product Chemistry

Background:

• Triple-negative breast cancer (TNBC) lacks specific prognostic markers and develops resistance to therapies.
• Naturally occurring compounds are explored for anti-cancer properties due to their safety and efficacy.
• Withaferin-A (WA), a phytochemical from Withania somnifera, possesses anti-inflammatory and anti-cancer activities.

Purpose of the Study:

• To review the mechanistic insights and recent updates on Withaferin-A (WA) in breast cancer, particularly TNBC.
• To highlight the anti-tumoral activities and chemotherapy-enhancing potential of WA against TNBC.
• To discuss the pharmacokinetic parameters and implications of WA in TNBC treatment.

Main Methods:

• Literature review of studies on Withaferin-A (WA) in breast cancer models.
• Analysis of in-vitro and in-vivo experimental data on WA's anti-tumoral effects.
• Examination of research on WA's combination therapy efficacy and pharmacokinetic properties.

Main Results:

• WA demonstrates significant anti-tumoral activities against experimental TNBC models.
• Combination of WA with chemotherapy enhances treatment efficacy in TNBC.
• WA exhibits promising pharmacokinetic profiles relevant for therapeutic applications.

Conclusions:

• Withaferin-A (WA) presents a viable therapeutic strategy for triple-negative breast cancer (TNBC).
• WA's ability to overcome tumor resistance mechanisms warrants further investigation.
• Further research into WA's pharmacokinetics and clinical applications is recommended for TNBC treatment.